Stempoint Capital’s Vaxcyte PCVX Stock Holding History

Stempoint Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-59,061	Closed	-$3.43M	–	103
2026 Q1	$3.43M	Buy	+59,061	New	+$3.21M	0.66%	44

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Stempoint Capital's PCVX Position: Q2 2026 in Review

Stempoint Capital sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 59,061 shares — an estimated $3.43M sold.

Stempoint Capital first reported a position in PCVX in Q1 2026 and held it in 1 quarter. The position peaked at $3.43M in Q1 2026. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Stempoint Capital reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
Stempoint Capital sold 59,061 Vaxcyte shares in Q2 2026, an estimated $3.43M.
Stempoint Capital first reported a position in Vaxcyte in Q1 2026 and held it in 1 quarter.
Stempoint Capital's Vaxcyte position peaked at $3.43M in Q1 2026.
332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.